2385 Stock Overview
Engages in the development of biomarkers in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Soiken Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥122.00 |
| 52 Week High | JP¥212.00 |
| 52 Week Low | JP¥107.00 |
| Beta | -0.12 |
| 1 Month Change | -9.63% |
| 3 Month Change | -12.23% |
| 1 Year Change | -26.06% |
| 3 Year Change | -62.46% |
| 5 Year Change | -80.19% |
| Change since IPO | -96.19% |
Recent News & Updates
Shareholder Returns
| 2385 | JP Personal Products | JP Market | |
|---|---|---|---|
| 7D | -3.9% | -1.7% | -1.5% |
| 1Y | -26.1% | -10.5% | 13.7% |
Return vs Industry: 2385 underperformed the JP Personal Products industry which returned -10.5% over the past year.
Return vs Market: 2385 underperformed the JP Market which returned 13.7% over the past year.
Price Volatility
| 2385 volatility | |
|---|---|
| 2385 Average Weekly Movement | 2.8% |
| Personal Products Industry Average Movement | 3.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 2385 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 2385's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 90 | n/a | www.soiken.com |
Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements comprising imidapeptides; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for pharmaceutical clinical research and epidemiology studies; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes.
Soiken Holdings Inc. Fundamentals Summary
| 2385 fundamental statistics | |
|---|---|
| Market cap | JP¥3.19b |
| Earnings (TTM) | -JP¥425.00m |
| Revenue (TTM) | JP¥5.43b |
0.6x
P/S Ratio-7.5x
P/E RatioIs 2385 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2385 income statement (TTM) | |
|---|---|
| Revenue | JP¥5.43b |
| Cost of Revenue | JP¥2.81b |
| Gross Profit | JP¥2.61b |
| Other Expenses | JP¥3.04b |
| Earnings | -JP¥425.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | -16.25 |
| Gross Margin | 48.18% |
| Net Profit Margin | -7.83% |
| Debt/Equity Ratio | 0% |
How did 2385 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 09:22 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Soiken Holdings Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Katsuro Hirozumi | Daiwa Securities Co. Ltd. |
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |